Literature DB >> 20802532

Hedgehog signaling maintains chemoresistance in myeloid leukemic cells.

K C S Queiroz1, R R Ruela-de-Sousa, G M Fuhler, H L Aberson, C V Ferreira, M P Peppelenbosch, C A Spek.   

Abstract

The development of resistance against chemotherapy remains one of the major challenges in the clinical management of leukemia. There is still limited insight into the molecular mechanisms that maintain the chemotherapy-resistant phenotype, despite the obvious clinical relevance that such knowledge would have. In this study, we show that the chemotherapy-resistant phenotype of myeloid leukemia cells correlates with activation of the Hedgehog (Hh) pathway, whereas in chemosensitive cells, such activation is less pronounced. Importantly, the overexpression of Hh pathway components induces chemoprotection and inhibition of the pathway reverts chemoresistance of Lucena-1 cells, apparently by interfering with P-glycoprotein-dependent drug resistance. Our data thus identify the Hh pathway as an essential component of multidrug resistance (MDR) myeloid leukemia and suggest that targeting the Hh pathway might be an interesting therapeutic avenue for overcoming MDR resistance in myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20802532     DOI: 10.1038/onc.2010.375

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  54 in total

1.  Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse.

Authors:  Andrew Kent; Sumithira Vasu; Derek Schatz; Natalie Monson; Steven Devine; Clayton Smith; Jonathan A Gutman; Daniel A Pollyea
Journal:  Blood Adv       Date:  2020-07-14

Review 2.  Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies.

Authors:  Luiza Handschuh
Journal:  J Oncol       Date:  2019-07-30       Impact factor: 4.375

3.  Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.

Authors:  Márcio Tavares; Sérgio Chacim; José Mário Mariz
Journal:  Ann Hematol       Date:  2020-10-01       Impact factor: 3.673

4.  A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS).

Authors:  David A Sallman; Rami S Komrokji; Kendra L Sweet; Qianxing Mo; Kathy L McGraw; Vu H Duong; Ling Zhang; Lisa Ann Nardelli; Eric Padron; Alan F List; Jeffrey E Lancet
Journal:  Leuk Res       Date:  2019-03-30       Impact factor: 3.156

5.  CCAAT/enhancer-binding protein δ facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-activating factor receptor-dependent manner.

Authors:  Janwillem Duitman; Marcel Schouten; Angelique P Groot; Keren S Borensztajn; Joost B Daalhuisen; Sandrine Florquin; Tom van der Poll; C Arnold Spek
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

6.  A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance.

Authors:  Zhiqiang Liu; Jingda Xu; Jin He; Yuhuan Zheng; Haiyan Li; Yong Lu; Jianfei Qian; Pei Lin; Donna M Weber; Jing Yang; Qing Yi
Journal:  Blood       Date:  2014-07-21       Impact factor: 22.113

Review 7.  Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy.

Authors:  Jenna L Carter; Katie Hege; Jay Yang; Hasini A Kalpage; Yongwei Su; Holly Edwards; Maik Hüttemann; Jeffrey W Taub; Yubin Ge
Journal:  Signal Transduct Target Ther       Date:  2020-12-18

Review 8.  The Hedgehog pathway: role in cell differentiation, polarity and proliferation.

Authors:  Yanfei Jia; Yunshan Wang; Jingwu Xie
Journal:  Arch Toxicol       Date:  2015-01-06       Impact factor: 5.153

Review 9.  Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells.

Authors:  Verline Justilien; Alan P Fields
Journal:  Clin Cancer Res       Date:  2015-02-01       Impact factor: 12.531

Review 10.  Hedgehog signaling pathway and cancer therapeutics: progress to date.

Authors:  Joshua M Ruch; Edward J Kim
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.